Abstract 425P
Background
Palonosetron (PALO) is a second-generation 5-hydroxytryptamine 3 receptor antagonist (5HT3RA) that has shown better efficacy than first-generation 5HT3RA (granisetron; GRA) in preventing chemotherapy-induced nausea and vomiting (CINV). PALO is usually administrated repeatedly when the patients have no nausea even though it is expensive as compared with GRA. However, we could reduce medical costs for chemotherapy if 5HT3RA conversion from PALO to GRA in the patient without having CINV is safe and tolerable.
Methods
We prospectively investigated patients receiving highly or moderately emetogenic chemotherapy (HEC or MEC) in combination with PALO for digestive organ cancers in accordance with guideline of Japan Society of Clinical Oncology. Patients assessed as complete response (CR) during the acute phase (0-24 h postchemotherapy) and the delayed phase (24-120 h postchemotherapy) in consecutive treatments were converted their antiemetic agents from PALO to GRA. We evaluated the incidence of CINV and the cost-effectiveness.
Results
Thirty five cases (madian age 73 years, female 51.4%, 18; pancreatic cancer, 8; colorectal cancer, 3; esophageal cancer, 3; gastric cancer, 3; biliary tract cancer) were enrolled at our institution between January 2018 and June 2019. Ten cases were administrated HEC (HEC group) and 25 cases were administrated MEC (MEC group). One case of HEC group and 2 cases of MEC group changed their chemotherapy regimens due to adverse events and progression of disease. Four cases of HEC group (40.0%) and 14 cases of MEC group (56.0%) were assessed as CR in consecutive treatments, thereafter their antiemetic agents were converted from PALO to GRA in the subsequent treatments. All of them continued their chemotherapy without the incidence of nausea and vomiting. Among the cases assessed as CR, we could save 111,935 Japanese yen (1,034.6 USD, range, 13,868-194,152 JPY) per case by conversion of 5HT3RA.
Conclusions
Our data indicated that the conversion of 5HT3RA is safe and also provide economic benefit in patients receiving HEC or MEC. When patients receiving HEC or MEC with PALO were assessed as CR, we should consider conversion of 5HT3RA.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Asahikawa medical University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
284P - Differences in disease characteristics and survival outcomes of follicular lymphoma in young adults and older population: An institutional analysis
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract
285TiP - Phase II, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667
Presenter: Christine Mauz-koerholz
Session: Poster display session
Resources:
Abstract
294P - Validation of the 8th edition of AJCC/UICC staging system for nasopharyngeal carcinoma: Results from a non-endemic cohort with long-term follow-up
Presenter: Li-rong Wu
Session: Poster display session
Resources:
Abstract
295P - Development and validation of M1 substages for previously untreated metastatic nasopharyngeal carcinoma
Presenter: Sik Kwan Chan
Session: Poster display session
Resources:
Abstract
296P - Nasopharyngeal carcinoma: A retrospective review of outcome in a single institution
Presenter: Wan Ping Ch' ng
Session: Poster display session
Resources:
Abstract
297P - Global longitudinal assessment of treatment outcomes in nasopharyngeal carcinoma (GLANCE-NPC) study
Presenter: Myung-Ju Ahn
Session: Poster display session
Resources:
Abstract
298P - Long-term complication and outcomes after induction chemotherapy with TPF followed by chemoradiotherapy for nasopharyngeal cancer
Presenter: Sang-Hee Cho
Session: Poster display session
Resources:
Abstract
299P - Weekly versus triweekly concurrent chemoradiation for nasopharyngeal cancer
Presenter: Sudibio Sudibio
Session: Poster display session
Resources:
Abstract
300P - Endoscopic nasopharyngectomy for localized stage I nasopharyngeal carcinoma
Presenter: Ming-Yuan Chen
Session: Poster display session
Resources:
Abstract
301P - Oncological outcome following 3 Drug NACT for Bucco-Alveolar carcinoma with Supra-notch ITF extension
Presenter: Karan Gupta
Session: Poster display session
Resources:
Abstract